Background {#Sec1}
==========

Classification criteria for rheumatoid arthritis (RA) have evolved over the decades. Positive serology receives special emphasis in the current criteria \[[@CR1]\]. In addition to rheumatoid factor (RF) and anti-cyclic citrullinated peptide (aCCP) antibodies, other RA-related antibodies have recently been identified. These include antibodies against carbamylated proteins (aCarP) \[[@CR2]\] and malonaldehyde-acetaldehyde \[[@CR3]\], albeit none of these are currently included in classification criteria or used in routine clinical practice.

Autoantibodies are believed to have a pathogenetic role in RA \[[@CR4]\]. In studies examining predictors, associating factors, or prevention of RA, seropositive and seronegative groups of patients seem to behave differently \[[@CR5]--[@CR7]\]. In treatment recommendations for RA, seropositivity is recognized as an indicator of severe disease and in these patients, the thresholds for earlier and more intensive/potent disease-modifying treatment are lower \[[@CR8]\]. It has become increasingly apparent that our knowledge concerning the pathogenesis, treatment responses and clinical course of seronegative RA, is limited \[[@CR9], [@CR10]\].

Up to 20-30 % of patients recruited into RA cohorts and clinical trials are seronegative \[[@CR11], [@CR12]\]. An exception is the Finnish Heinola Rheumatism Foundation Hospital early RA cohort from the middle 1970's, which included long-term (25 years) follow-up of seropositive patients only, as experienced rheumatologists were convinced that seropositive disease (positive RF alone at that time) is the only true presentation of the disease \[[@CR13]\]. This formed the basis of our interest in observing the clinical presentation of seronegative RA.

Observations in our early RA cohorts indicate that long-term radiographic outcomes are different between seropositive and seronegative patients \[[@CR14]\]. The natural course of seropositive disease is that of progressive erosions \[[@CR15]\], while even in the long-term (e.g. over 20 years), seronegative patients do not present with marked erosions \[[@CR16]\]. However, among \>3000 patients included in the Jyvaskyla Central Hospital clinical RA database since the 1990's we identified a few consistently RF and aCCP negative individuals with a particular presentation of aggressive, destructive disease. Four cases are presented in detail herein.

Case presentation {#Sec2}
=================

Case 1 {#Sec3}
------

Demographics: 68 year old female, diagnosed at the age of 50 in 10.1996. Shopkeeper, work disabled since the diagnosis; former smoker.

Initial presentation: Swelling and tenderness starting in the right knee in 01.1996. Intra-articular glucocorticoid injections administered into the right knee four times, until arthroscopy in 08.1996 with macro- and microscopic finding of synovitis. Joint symptoms gradually evolved resulting in the diagnosis of clinical polyarthritis in 10.1996. See Fig. [1a](#Fig1){ref-type="fig"}.Fig. 1**a** Initial clinical presentation of Patient 1. **b** Progress of Patient 1. **c** 1-5. Most recent radiographs of Patient 1 (16-19 years from diagnosis)

Comorbidities and Joint surgery: See Table [1](#Tab1){ref-type="table"}.Table 1Medical history of Patient 1Data extracted25.08.2015IDCase 1Age, Gender68, FemaleWork statusPensioner since diagnosisDiagnosisRheumatoid ArthritisDiagnosis criteria- Symptoms: 1.1996- Clinical diagnosis of RA: 10.1996Highest RF (IgM)Negative (9) 3.2012Highest (aCCP)Negative (4) 8.2009aCarPNegative 7.2015HLA-B27PositiveDrug (now)Methotrexate 1.2015- 7,50 mg Subcutaneous Once a weekAdalimumab (Humira) 1.2015- 40,00 mg Subcutaneous Every 2. weekPrednisolone 10.2013- 5,00 mg Peroral Every dayComorbidityVertebral fracture 10.2005Herpes zoster infection 9.2002Arm fracture, not wrist 8.2001Osteopenia by DXA 2001Cholelithiasis 3.1998Arterial hypertension 11.1996Fibromyalgia 7.1990Lumbago/dorsalgia/sciatica 1980Migraine - Before rheuma diagnosisSurgeryLeft ankle Arthrodesis 11.2011Right ankle Arthrodesis 3.2011Left MTP Arthrodesis 3.2007Right MTP Arthrodesis 3.2007Left knee Arthroplasty 10.2003Left knee Synovectomy 5.2003Right knee Arthroscopy and Synovectomy 10.2002Right knee Rearthroplasty 12.2001Right knee Arthroplasty 4.1998Right knee Other surgery 8.1996

Medications: Current medications, see Table [1](#Tab1){ref-type="table"}. Previous synthetic and biologic disease modifying anti rheumatic drug (DMARD) treatments were (in order of use): sulfasalazine, gold intra muscular (IM), podofyllotoxin (Reumacon), ciclosporin, cyclosphosphamide, leflunomide, infliximab, azathioprine, and hydroxychloroquine, see Fig. [1b](#Fig1){ref-type="fig"}.

Progress: See Fig. [1b](#Fig1){ref-type="fig"}. Most recent values for patient reported outcomes and disease activity: HAQ 1.63, pain 35, fatigue 6, patient global 30, ESR 16, CRP 2, DAS28 3.4 indicating moderate disease activity.

Radiographic features: Radiographs on presentation showed no joint damage. The most recent radiographs of hands, wrists, feet, and ankles, taken 16-19 years after diagnosis, are shown in Fig. [1c](#Fig1){ref-type="fig"}. Prominent features include joint space narrowing and subluxation of bones in left wrist and meta carpo phalangeal MCP joints, destruction and operation of subtalar, talonavicular and naviculo-cuneiforme joints, as well as right ankle. Typical erosions, seen as in seropositive RA patients are missing.

Case 2 {#Sec4}
------

Demographics: 39 year old female, diagnosed at the age of 16 in 07.1992. Working as a civil engineer. Never smoked.

Initial presentation: The patient sustained a left knee strain while running in 3.1992; symptoms spontaneously resolved within 3 weeks. She was noted to have hyperextension of the left knee in 6.1992 with 7.1992 with synovial fluid aspiration showing 14.000 leucocytes (98 % granulocytes) and a clinical presentation of polyarthritis as shown in Fig. [2a](#Fig2){ref-type="fig"}.Fig. 2**a** Initial clinical presentation of Patient 2. **b** Progress of Patient 2. **c** 1-6. Most recent radiographs of Patient 2 (20-23 years from diagnosis; neck radiographs in 2007)

Comorbidities and Joint surgery: See Table [2](#Tab2){ref-type="table"}.Table 2Medical history of Patient 2Data extracted15.09.2015IDCase 2Age, Gender39, FemaleWork statusFull-time workDiagnosisRheumatoid ArthritisDiagnosis criteria- Symptoms: 3.1992- Clinical diagnosis of RA: 7.1992Highest RF (IgM)Negative (8) 2.2012Highest (aCCP)Negative (0) 2.2012aCarPNegative 7.2015HLA-B27NegativeDrug (now)Etanercept (Enbrel) 1.2013- 50,00 mg Subcutaneous Once a weekMethotrexate 5.2011- 15,00 mg Subcutaneous Once a weekPrednisolone 4.2004- 5,00 mg Peroral Every dayComorbidityNeutropenia 12.2012 - 12.2012Viral infection 12.2012Osteopenia by bone density by DXA 3.2012SurgeryNeck Arthrodesis 8.2007Right wrist Tenosynovectomy 10.1995

Medications. Current medications see Table [2](#Tab2){ref-type="table"}. Previous DMARD treatments included (in order of use): i.m. gold, sulphasalazine, podofyllotoxin (Reumacon), hydroxychloroquine, infliximab, and rituximab see Fig. [2b](#Fig2){ref-type="fig"}.

Progress: See Fig. [2b](#Fig2){ref-type="fig"}. Most recent values for patient reported outcomes and disease activity: HAQ 0.13, pain 8, fatigue 12, patient global 9, ESR 2, CRP 5, DAS28 2.1 indicating remission.

Radiographic features: Initial joint radiographs on presentation showed no damage. The most recent radiographs 20-23 years after diagnosis are presented in Fig. [2c](#Fig2){ref-type="fig"}. The prominent features are damage in wrists, subluxation of right MCP II, damage of talonavicular and naviculo-cuneiform joints, but minimal erosive changes characteristic of seropositive RA.

Radiographs of the neck in 2007 indicated a sliding atlanto axial subluxation of 7 mm in head bending forward --position. An MRI of the neck showed no active pannus and no erosions in the dens.

Case 3 {#Sec5}
------

Demographics: 63 year old female, diagnosed at the age of 28 in 05.1980. Cashier, work disabled since September 1989. Never smoked.

Initial presentation: Temporary pains and aches in knees, wrists, and fingers since the age of 15, and increasing several months prior to the diagnosis in 05.1980 when she presented with a polyarthritis as shown in Fig. [3a](#Fig3){ref-type="fig"}.Fig. 3**a** Initial clinical presentation of Patient 3. **b** Progress of Patient 3. **c**1-4. Most recent radiographs of Patient 3 (32-35 years from diagnosis)

Comorbidities and Joint surgery: See Table [3](#Tab3){ref-type="table"}.Table 3Medical history of Patient 3Data extracted14.09.2015IDCase 3Age, Gender63, FemaleWork statusDisabled pensioner since 9.1989DiagnosisRheumatoid ArthritisDiagnosis criteria- Symptoms: 6.1979- Clinical diagnosis of RA: 5.1980Highest RF (IgM)Negative (9) 6.2014Highest (aCCP)Negative (0) 9.2014aCarPNegative 7.2015HLA-B27NegativeDrug (now)Infliximab (Inflectra) 2.2014- 300,00 mg Intravenous Every 8. weekPrednisolone 2.2011- 2,50 mg Peroral Every dayMethotrexate 5.2002- 10,00 mg Peroral Once a weekComorbidityHyperlipidemia 4.2011Hypothyroidism 4.2011Osteoporosis by DXA 11.1997Arterial hypertension 6.2011SurgeryLeft elbow Prosthesis 2.2011Right elbow Prosthesis 04.10.2010Left MCP-1 Arthrodesis 3.2003Left MCP-4 Prosthesis 3.2003Left PIP-1 Prosthesis 3.2003Left PIP-5 Arthrodesis 3.2003Right DIP-2 Arthrodesis 1.2003Right MCP-1 Arthrodesis 1.2003Right MCP-3 Prosthesis 1.2003Right MCP-4 Prosthesis 1.2003Right PIP-5 Arthrodesis 1.2003Right shoulder Prosthesis 12.1997Left shoulder Prosthesis 9.1997Right ankle Arthrodesis 9.1996Right ankle Arthrodesis 1.1996Left hip Prosthesis 11.1995Right ankle Arthrodesis 6.1995Right hip Prosthesis 4.1995Left ankle Arthrodesis 5.1994Right MCP-3 Prosthesis 11.1993Right MCP-4 Prosthesis 11.1993Right MCP-5 Prosthesis 11.1993Right PIP-1 Arthrodesis 11.1993Left ankle Arthrodesis 3.1993Right MTP -- Joint resection 1990Left MTP -- Joint resection 1990Right wrist Tenosynovectomy 2.1981

Medications. Current medications are presented in Table [3](#Tab3){ref-type="table"}. Previous DMARD treatments were (in order): gold i.m., sulphasalazine, auranofin, hydroxychloroquine, D-penicillamine, azathioprine, podofyllotoxin (Reumacon), ciclosporin, cyclophosphamide, chlorambucil, leflunomide, and infliximab (Remicade) see Fig. [3b](#Fig3){ref-type="fig"}.

Progress: See Fig. [3b](#Fig3){ref-type="fig"}. Most recent values for patient reported outcomes and disease activity: HAQ 1.38, pain 0, fatigue 0, patient global 0, ESR 33, CRP 10, DAS28 3.0 indicating low disease activity.

Radiographic features: No radiographic joint damage was seen at initial presentation. The most recent radiographs 32-35 years after diagnosis are presented in Fig. [3c](#Fig3){ref-type="fig"} and show prominent damage in the, wrists, ankle/subtalar/upper forefeet areas, as well as status post orthopaedic surgery in many joints.

Case 4 {#Sec6}
------

Demographics: 60 year old female. Diagnosed at the age of 28 in 12.1982. Waitress, work disabled since 1995, former smoker.

Initial presentation: Symptoms started two years before diagnosis, with synovitis in both knees. Two months prior to diagnosis, symptoms began in other joints with clinical polyarthritis in 12.1982 as presented in Fig. [4a](#Fig4){ref-type="fig"}.Fig. 4**a** Initial presentation of Patient 4. **b** Progress of Patient 4. **c** 1-4. Most recent radiographs of Patient 4 (30-33 years from diagnosis)

Comorbidities and Joint surgery: See Table [4](#Tab4){ref-type="table"}.Table 4Medical history of Patient 4Data extracted14.09.2015IDCase 4Age, Gender61, FemaleWork statusPensioner since 1995DiagnosisRheumatoid ArthritisDiagnosis criteria- Symptoms: 6.1980- Clinical diagnosis of RA: 12.1982Highest RF (IgM)Negative (8) 4.2009Highest (aCCP)Negative (4) 4.2009aCarPNegative 7.2015HLA-B27PositiveDrug (now)Abatacept (Orencia) 12.2013- 125,00 mg Subcutaneous Every weekEtanercept (Enbrel) 10.2012- 50,00 mg Subcutaneous Every 10. dayPrednisolone 5.2007- 5,00 mg Peroral Every dayMethotrexate 12.1994- 20,00 mg Peroral Once a weekComorbidityColon diverticulitis 8.2013Urinary tract infection 7.2012Bacterial infection 6.2012Pulmonary embolism 8.2011Pulmonary embolism 12.2010Asthma 11.2008Hyperlipidemia 1.2008Arterial hypertension 6.2007Osteoporosis by DXA measurement 1.1998SurgeryRight hip Prosthesis 5.1999Left knee Prosthesis 2.1999Left hip Prosthesis 1.1997

Treatment: Current medications are presented in Table [4](#Tab4){ref-type="table"}. Previous DMARD treatments were (in order): Im gold, sulfasalazine, cyclosporine, infliximab, and adalimumab, see Fig. [4b](#Fig4){ref-type="fig"}.

Progress: See Fig. [4b](#Fig4){ref-type="fig"}. Most recent values for patient reported outcomes and disease activity: HAQ 1.75, pain 59, fatigue 40, patient global 50, ESR 22, CRP 5, DAS28 2.9 indication low disease activity.

Radiographic features: The most recent radiographs of hands, wrists, feet, and ankles, 30-33 years after diagnosis, are presented in Fig. [4c](#Fig4){ref-type="fig"}. Destruction of wrists and ankle/subtalar area are prominent, with minimal/no erosions typical for seropositive RA.

Discussion {#Sec7}
==========

These cases all share a common feature: that of a severe, destructive disease in seronegative RA with involvement primarily of the wrists, sub-talar and ankle joints, as well as large joints. All these patients were negative with regard to RF, aCCP, and aCarP. Two cases were HLA-B27 positive but despite this, the clinical presentation (signs and symptoms) and radiographs of the sacro-iliac joints did not support a diagnosis of ankylosing spondylitis (AS) or other spondyloarthritides in these individuals.

Seronegative RA has been in focus of only a few cohorts and rarely in detail, to reveal various aspects of outcomes \[[@CR9]\]. Again, an exception is from the Heinola group, which reported long-term outcomes of non-specific seronegative oligoarthritis in patients with a 23 year follow-up \[[@CR16]\]. Based on patient history, radiographs and clinical status at the follow-up visit, they re-classified the 64 patients and found one case each of RA, systemic lupus erythematosus and ankylosing spondylitis, two cases of post-traumatic arthritis, four cases of osteoarthritis, and six cases of possible reactive arthritis. Of the remaining 49 patients, 15 were HLA-B27 positive and 16 had at least one of the psoriasis-related HLA antigens. Seven patients had minor erosions in their hands or feet joints. One HLA-B27 positive patient had developed bilateral sacroilitis by the evaluation at 23 years. Functional capacity of the patients was well retained. Compared to this Heinola seronegative cohort, our patients present a more severe destructive disease, and to date, remain un-classified.

To our experience, patients with destructive seronegative (RF, aCCP negative) RA - as this disease entity can be referred to - are rare. Among our approximately 3000 RA patients, of whom 30 % are seronegative, only a few seem to present with such degree of destructive disease. However, over the years it is possible that similar cases have been missed, as prior to the era of aCCP analyses, a proportion of RF negative cases demonstrated a typical RF positive course and were later revealed to be aCCP positive. Although destructive seronegative RA is rare, it can have devastating consequences and early recognition and intensive treatment is paramount.

The current clinical status of the patients presented in this report indicates considerable functional loss with a HAQ \> 1.5 in three of the four patients. Despite this, disease activity appears to be under at least some degree of control with DAS28 values between 2.1 to 3.4. Current treatment in all four patients includes prednisolone, methotrexate and biologic agents (combination of two biologic agents in [Case 4](#Sec5){ref-type="sec"}).

The radiological progression of joint damage in these patients presents major cartilage destruction and loss and with minor bony erosions of joints. In fact, it could even be argued that the radiographic destruction seen in these cases resembles that of advanced seronegative juvenile polyarthritis.

Conclusions {#Sec8}
===========

Through a detailed description of four destructive seronegative (for RF, aCCP and aCarP) RA cases from disease-onset and up to 35 years from diagnosis, this report could shed more light on the disease presentation, course and outcomes of such patients. We hope to inform the reader of this particular sub-type of inflammatory arthritis which can result in devastating patient outcomes and therefore needs prompt identification and treatment, similar to seropositive disease. This report justifies the undertaking of further research on the pathogenesis and identification of possible biomarkers for this type of arthropathy, which could be invaluable in firstly understanding disease behavior and course and secondly in treatment stratification.
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